)
Visual
test
Janux Therapeutics
Janux Therapeutics (JANX) investor relations material
Janux Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary26 Feb, 2026
Executive summary
Advanced clinical programs with JANX007 and JANX008, including expansion into new patient cohorts and tumor settings.
Initiated Phase 1 study of JANX011 in healthy volunteers.
Entered a major collaboration and exclusive license agreement with Bristol Myers Squibb for a novel solid tumor therapeutic.
Strengthened leadership with the appointment of a new Chief Medical Officer.
Financial highlights
Cash and short-term investments totaled $966.6 million as of December 31, 2025, down from $1.03 billion at year-end 2024.
Research and development expenses were $31.5 million for Q4 and $125.9 million for the year, up from $20.8 million and $68.4 million in 2024.
General and administrative expenses were $10.9 million for Q4 and $41.8 million for the year, compared to $8.2 million and $41.0 million in 2024.
Net loss was $31.9 million for Q4 and $113.6 million for the year, compared to $20.2 million and $69.0 million in 2024.
Collaboration revenue was $10.0 million for Q4 and $10.6 million for the year.
Outlook and guidance
Additional clinical data for JANX007 and JANX008 expected in 2026.
Initial clinical update from JANX011 Phase 1 study anticipated by year-end 2026.
JANX007: Rationale for PARP-refractory mCRPC
Source of 2025 collaboration revenue
New programs entering clinic in 2026
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Janux Therapeutics
- 100% PSA50 and 63% PSA90 achieved, with robust safety and expansion plans underway.JANX
Status Update12 Jan 2026 - Durable efficacy, deep PSA reductions, and manageable safety seen in mCRPC, especially taxane-naive.JANXInvestor Update5 Dec 2025
- Board recommends annual say-on-pay votes and robust governance at the 2025 meeting.JANXProxy Filing2 Dec 2025
- Virtual annual meeting to vote on directors, auditor, and executive pay, with board support.JANXProxy Filing2 Dec 2025
- Non-employee director compensation policy updated with new cash and equity awards for 2024.JANXProxy Filing2 Dec 2025
- Innovative bispecifics pipeline advances in oncology and autoimmune disease with strong data and funding.JANXR&D Day 202516 Nov 2025
- Net loss increased on higher R&D, with $10M milestone revenue and $989.8M in liquidity.JANXQ3 20256 Nov 2025
- Q2 2025 net loss widened to $33.9M, but cash reserves of $996.8M remain strong.JANXQ2 20257 Aug 2025
- Q3 net loss was $28.1M; cash reserves of $658.8M support ongoing clinical trials.JANXQ3 202413 Jun 2025
Next Janux Therapeutics earnings date
Q1 20268 May, 2026
Janux Therapeutics
Next Janux Therapeutics earnings date
Q1 20268 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage